Driven by DRG’s oncology expertise and real-world data capabilities, the Real World Brand Tracker is an interactive dashboard of regularly updated U.S. claims data that monitors and highlights the shifting market dynamics and the impact of events on immune checkpoint inhibitor prescribing.

QUESTIONS ANSWERED

How is the uptake for individual brands changing over time and across different U.S. regions and individual states?

Which brand is winning, and how does that vary by indication?

How does the dynamic regulatory environment for immune checkpoint inhibitor brands in the United States affect prescribing patterns of currently approved brands by indication?

What is the average claim charge for each brand? How does this compare to the reimbursed amount? How does each of these metrics vary by payer type?

In which types of facilities are patients receiving these brands?

KEY BENEFITS AND USES

Understand evolving market dynamics and correlate clinical and regulatory events to brand use by indication.

Track number of patients treated with immune checkpoint inhibitor brands over time.

Segment the data in multiple ways, including by state and treatment setting, to reveal pockets of opportunity.

Visualize trends in payer metrics including total claim amount, total claim paid, and top payers for immune checkpoint inhibitors.

Design appropriate clinical trial strategies based on rapidly evolving standards in treatment practices, as revealed by claims data.

Uncover pockets of opportunity for improved penetration and identify segments where brands are performing poorly.

Table of contents

  • Real World Brand Tracker - Real World Brand Tracker - Real World Brand Tracker
    • About Real World Brand Tracker
      • Real World Brand Tracker: Q4 2020 Data Summary
    • Dashboard

Author(s): Priyanka Mehra, B.Tech.

Priyanka Mehra, B.Tech., is an analyst on the Oncology team at DRG, part of Clarivate. She has more than five years of experience working in pharmaceutical research and analytics, involving the management and execution of various strategic analysis projects for multiple oncology indications, secondary and primary research, and competitive intelligence. Prior to joining DRG, she worked as an associate consultant with Prescient Healthcare Group, where she was involved with biosimilar projects for global pharmaceutical clients and designed brand and commercial strategies in a variety of therapy areas, including oncology, immunology, and inflammatory disease. Prior to Prescient, she was a senior analyst at Smart Analyst, where she worked on indication prioritization and clinical landscapes for major oncology indications, including non-small-cell lung cancer, colorectal cancer, and melanoma. Ms. Mehra obtained her bachelor’s degree in biotechnology from Amity University in India.